Aurora a kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4097-4109

  Zullo, Kelly M ^a   Guo, Yige ^a   Cooke, Laurence ^b   Jirau Serrano, Xavier ^a   Mangone, Michael ^a   Scotto, Luigi ^a   Amengual, Jennifer E ^a   Mao, Yinghui ^a   Nandakumar, Renu ^a   Cremers, Serge ^a   Duong, Jimmy ^c   Mahadevan, Daruka ^b   O'Connor, Owen A ^a  

^a Department of Medicine   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; IXAZOMIB; PRALATREXATE; ROMIDEPSIN; 10-PROPARGYL-10-DEAZAAMINOPTERIN; AMINOPTERIN; AURORA A KINASE; AZEPINE DERIVATIVE; BORON DERIVATIVE; DEPSIPEPTIDE; GLYCINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B-CELL LYMPHOMA CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINESIS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TUMOR LEVEL; HIGH THROUGHPUT SCREENING; IC50; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; T CELL LYMPHOMA; T-CELL LYMPHOMA CELL LINE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL CYCLE; CENTROSOME; CHEMISTRY; DRUG SCREENING; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOMA, T-CELL; METABOLISM; MITOSIS; SCID MOUSE; SPINDLE APPARATUS; TUMOR CELL LINE; ULTRASTRUCTURE;

AMINOPTERIN; ANIMALS; AURORA KINASE A; AZEPINES; BORON COMPOUNDS; CELL CYCLE; CELL LINE, TUMOR; CENTROSOME; CYTOKINESIS; DEPSIPEPTIDES; DRUG SYNERGISM; GLYCINE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INHIBITORY CONCENTRATION 50; KAPLAN-MEIER ESTIMATE; LYMPHOMA, T-CELL; MICE; MICE, SCID; MITOSIS; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SPINDLE APPARATUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941008507     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0033     Document Type: Article

References (37)

1. Mak V, Hamm J, Chhanabhai M., Shenkier T, Klasa R, Sehn L.H., et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013; 31:1970-6.
2. O'Connor O.A., Pro B, Pinter-Brown L, Bartlett N., Popplewell L, Coiffier B, et al Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29:1182-9.
3. Horwitz SM, Advani RH, Bartlett N.L., Jacobsen ED, Sharman JP, O'Connor OA, et al. Objective responses in relapsed T-cell lymphomas with singleagent brentuximab vedotin. Blood 2014; 123:3095-100.
4. Vader G, Lens SM The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008; 1786:60-72.
5. Camacho E, Bea S, Salaverria I., Lopez-Guillermo A, Puig X, Benavente Y., et al. Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma. Int J Cancer 2006; 118:357-63.
6. Kanagal-Shamanna R., Lehman NL, O'Donnell JP, Lim MS, Schultz D.S., Chitale DA, et al. Differential expression of aurora-A kinase in T-cell lymphomas. Mod Pathol 2013; 26:640-7.
7. Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014; 32:44-50.
8. Tomita M, Mori N. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T cells in vitro. Cancer Sci 2010; 101:1204-11.
9. Qi W, Spier C, Liu X., Agarwal A, Cooke LS, Persky D.O., et al. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 2013; 37:434-9.
10. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L., Zhang M, Hoar KM, et al Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacody-namic assays. Clin Cancer Res 2011; 17:7614-24.
11. Marchi E, Paoluzzi L, Scotto L., Seshan VE, Zain JM, Zinzani PL, et al Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 2010; 16:3648-58.
12. Paoluzzi L, Scotto L, Marchi E., Zain J, Seshan VE, O'Connor OA. Romi-depsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010; 16:554-65.
13. Amengual JE, Clark-Garvey S, Kalac M., Scotto L, Marchi E, Neylon E., et al. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood 2013; 122: 2104-13.
14. Kalac M, Scotto L, Marchi E., Amengual J, Seshan VE, Bhagat G, et al HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 2011; 118:5506-16.
15. Deng C, Lipstein M, Rodriguez R., Serrano XO, McIntosh C, Tsai WY, et al The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-kB. Clin Cancer Res 2015; 21: 134-45.
16. Jain S, Jirau-Serrano X, Zullo K., Scotto L, Palermo CF, Satstra S.A., et al. A multimodality imaging approach confirms marked activity of pralatrexate and romidepsin in combination in a bioluminescent murine model of human T-cell lymphoma. Clin Cancer Res 2015 Feb 12. [Epub ahead of print].
17. Keith CT, Borisy AA, Stockwell BR Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005; 4:71-8.
18. Borisy AA, Elliott PJ, Hurst N.W., Lee MS, Lehar J, Price ER, et al Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A 2003; 100:7977-82.
19. Mahadevan D, Morales C, Cooke L.S., Manziello A., Mount DW, Persky DO, et al. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2. PLoS ONE 2014; 9:e95184.
20. Frew AJ, Johnstone RW, Bolden JE Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280:125-33.
21. Burgess AJ, Pavey S, Warrener R., Hunter LJ, Piva TJ, Musgrove EA, et al Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 2001; 60:828-37.
22. Estevam J, Danaee H, Liu R, Ecsedy J, Trepicchio WL, Wyant T. Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition. J Immunol Methods 2011; 363:135-42.
23. Cha TL, Chuang MJ, Wu S.T., Sun GH, Chang SY, Yu DS, et al Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 2009; 15:840-50.
24. Taddei A, Maison C, Roche D., Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting dea-cetylases. Nat Cell Biol 2001; 3:114-20.
25. Palani S, Patel M, Huck J., Zhang M, Balani SK, Yang J, et al Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Che-mother Pharmacol 2013; 72:1255-64.
26. Marumoto T, Hirota T, Morisaki T., Kunitoku N, Zhang D, Ichikawa Y., et al. Rolesofaurora-A kinaseinmitotic entry and G2checkpointinmammalian cells. Genes Cells 2002; 7:1173-82.
27. Park JH, Jong HS, Kim S.G., Jung Y., Lee KW, Lee JH, et al. Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med 2008; 86:117-28.
28. Kretzner L, Scuto A, Dino P.M., Kowolik CM, Wu J, Ventura P, et al Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res 2011; 71:3912-20.
29. Ishii S, Kurasawa Y, Wong J., Yu-Lee LY. Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc Natl Acad Sci U S A 2008; 105:4179-84.
30. Magnaghi-Jaulin L., Eot-Houllier G, Fulcrand G., Jaulin C. Histone deace-tylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res 2007; 67:6360-7.
31. Grewal C, Hickmott J, Rentas S., Karagiannis J. A conserved histone deacetylase with a role in the regulation of cytokinesis in Schizosaccharomyces pombe. Cell Div 2012; 7:13.
32. Zeitlin SG, Shelby RD, Sullivan KF CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis. J Cell Biol 2001; 155:1147-57.
33. Valdivia MM, Hamdouch K, Ortiz M., Astola A. CENPA a genomic marker for centromere activity and human diseases. Curr Genomics 2009; 10: 326-35.
34. Amiri-Kordestani L., Luchenko V, Peer C.J., Ghafourian K., Reynolds J, Draper D, et al Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res 2013; 19:4499-507.
35. Shen L, Au WY, Wong K.Y., Shimizu N., Tsuchiyama J, Kwong YL, et al Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells. Mol Cancer Ther 2008; 7:3807-15.
36. Paoluzzi L, Gonen M, Bhagat G., Furman RR, Gardner JR, Scotto L, et al The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008; 112: 2906-16.
37. O'Connor O.A., Smith EA, Toner L.E., Teruya-Feldstein J, Frankel S, Rolfe M., et al. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 2006; 12:2902-11.